The U.S. Food and Drug Administration (FDA) approved the addition to the label on March 8 based on a study from Wegovy's manufacturer, Novo Nordisk, showing that the drug lowered the risk of heart attack, stroke, or dying of heart-related issues in this population by 20% compared to people receiving placebo.
This is an entirely new pathway to harness, of addressing obesity and its metabolic complications, said Dr. Amit Khera, director of the Preventive Cardiology Program at the University of Texas Southwestern Medical Center, after the results o
[
add
]
[
|
|
...
]